strength today

With the focus of the company shifting to ACV1, it appears that the share price may have found just a bit of strength as the stock moved up today on good volume.

This company may wind up doing OK in spite of itself.

I don't expect much over the next couple months, and we could still see new lows under 13 cents in the interim, but good news in June could send the shares to 20 cents or even to 30 cents optimistically by September.

Those who point out that ACV1 is still six years or more away from commercialisation are not considering that the drug could contribute earnings to the company within two years on the basis of licensing fees and milestone payments.

If the company doesn't succumb to delusions of grandeur and try to take the drug all the way on its own, that is.